Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cholesterol: Significance and Regulation

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

Journal of clinical lipidology·2022

Same author

Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH).

Journal of clinical lipidology·2021

Same author

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies.

Cardiology and therapy·2020

Same author

Authors' response to letter by Anagnostis and Stevenson, "Is there a role for menopausal hormone therapy in a woman with increased lipoprotein(a) concentrations?"

Journal of clinical lipidology·2020

Same author

"Zero": The New Superhero or Superhero in Training?

Journal of the American College of Cardiology·2019

Same author

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

Journal of clinical lipidology·2019

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

Cholesterol and coronary events. The current thinking.

Peter H Jones¹

¹Baylor College of Medicine, Houston, TX 77030, USA. jones@bcm.tmc.edu

Postgraduate Medicine

|August 12, 2009

Summary

This summary is machine-generated.

Lowering low-density lipoprotein cholesterol (LDL-C) is crucial for preventing coronary heart disease (CHD). Statins are effective, with ongoing trials exploring even lower LDL-C targets for optimal patient outcomes.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Experiment Videos

Last Updated: Jun 21, 2026

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

Cardiology
Pharmacology
Preventive Medicine

Background:

The clinical benefit of lowering low-density lipoprotein cholesterol (LDL-C) for coronary heart disease (CHD) prevention is well-established.
Statins are the primary pharmacologic agents for LDL-C reduction.
Updated guidelines emphasize aggressive LDL-C lowering for CHD patients and risk-equivalent individuals.

Purpose of the Study:

To review the established and evolving role of LDL-C lowering in CHD prevention.
To discuss the implications of updated National Cholesterol Education Program guidelines.
To explore the potential for greater LDL-C reduction with statins and emerging therapies.

Main Methods:

Review of current clinical guidelines and scientific literature.
Discussion of ongoing clinical trials evaluating intensive LDL-C lowering.
Analysis of the role of high-density lipoprotein cholesterol (HDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) in CHD risk.

Main Results:

Optimal LDL-C levels are defined as <100 mg/dL for high-risk patients.
The benefit of lowering LDL-C substantially below 100 mg/dL is under investigation in ongoing trials.
Statins can achieve >60% LDL-C reduction and favorably impact HDL-C and non-HDL-C levels.

Conclusions:

Statin therapy is appropriate for a broad spectrum of dyslipidemic patients.
Newer guidelines identify low HDL-C (<40 mg/dL) and elevated non-HDL-C as significant CHD risk factors.
Further research is needed to determine optimal LDL-C targets for maximum clinical benefit.